Cost-effectiveness and budget impact of lopinavir/ritonavir and atazanavir plus ritonavir regimens based on 48-week results from the CASTLE study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-2652
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cost-effectiveness and budget impact of lopinavir/ritonavir and atazanavir plus ritonavir regimens based on 48-week results from the CASTLE study ; volume:11 ; number:1 ; day:10 ; month:11 ; year:2008 ; pages:1 ; date:12.2008
Journal of the International AIDS Society / International AIDS Society ; 11, Heft 1 (10.11.2008), 1, 12.2008
- Urheber
-
Simpson, KN
- Beteiligte Personen und Organisationen
-
Rajagopalan, R.
Dietz, B.
SpringerLink (Online service)
- DOI
-
10.1186/1758-2652-11-S1-P311
- URN
-
urn:nbn:de:1111-2016052053997
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Simpson, KN
- Rajagopalan, R.
- Dietz, B.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir
Nirmatrelvir Plus Ritonavir: First Approval
Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir
Lopinavir/ritonavir monotherapy in clinical practice
Scutellaria baicalensis decreases ritonavir-induced nausea
Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors
Pharmakokinetik der Protease-Inhibitoren Lopinavir und Ritonavir
Correction to: Nirmatrelvir Plus Ritonavir: First Approval
Minority M184V variants in women exposed to 3TC/FTC-containing lopinavir-ritonavir (LPVr) regimens in pregnancy
Ombitasvir/Paritaprevir/Ritonavir: Nutzenbewertung gemäß § 35a SGB V
Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir
Nirmatrelvir Plus Ritonavir: First Approval
Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir
Lopinavir/ritonavir monotherapy in clinical practice
Scutellaria baicalensis decreases ritonavir-induced nausea
Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors
Pharmakokinetik der Protease-Inhibitoren Lopinavir und Ritonavir
Correction to: Nirmatrelvir Plus Ritonavir: First Approval
Minority M184V variants in women exposed to 3TC/FTC-containing lopinavir-ritonavir (LPVr) regimens in pregnancy
Ombitasvir/Paritaprevir/Ritonavir: Nutzenbewertung gemäß § 35a SGB V
Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir
Nirmatrelvir Plus Ritonavir: First Approval
Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir
Lopinavir/ritonavir monotherapy in clinical practice
Scutellaria baicalensis decreases ritonavir-induced nausea
Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors
Pharmakokinetik der Protease-Inhibitoren Lopinavir und Ritonavir
Correction to: Nirmatrelvir Plus Ritonavir: First Approval
Minority M184V variants in women exposed to 3TC/FTC-containing lopinavir-ritonavir (LPVr) regimens in pregnancy